Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis

British Journal of Pharmacology

Volumn 163, Issue 4, 2011, Pages 804-814

  Schlimmer, N ^a   Kratz, M ^a   Bohm M ^a   Baumhakel M ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

endothelial function; erectile function; ramipril; telmisartan

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; RAMIPRIL; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SINUS; ARTICLE; ASCENDING AORTA; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFECT; ENDOTHELIUM; LIPID PEROXIDATION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; WILD TYPE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; ATHEROSCLEROSIS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CHOLESTEROL; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; FREE RADICALS; LIPID PEROXIDES; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE III; RAMIPRIL; RENIN-ANGIOTENSIN SYSTEM;

EID: 79958023299     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01267.x     Document Type: Article

References (44)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Baumhakel M, Bohm M, (2007). Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients. Int J Clin Pract 61: 361-366.
3. Baumhakel M, Custodis F, Schlimmer N, Laufs U, Bohm M, (2008). Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan. J Pharmacol Exp Ther 327: 692-698.
4. Becker AJ, Uckert S, Stief CG, Truss MC, Machtens S, Scheller F, et al,. (2001). Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology 57: 193-198. (Pubitemid 32065855)
5. Behr-Roussel D, Darblade B, Oudot A, Compagnie S, Bernabe J, Alexandre L, et al,. (2006). Erectile dysfunction in hypercholesterolemic atherosclerotic apolipoprotein E knockout mice. J Sex Med 3: 596-603.
6. Billups KL, Bank AJ, Padma-Nathan H, Katz SD, Williams RA, (2008). Erectile dysfunction as a harbinger for increased cardiometabolic risk. Int J Impot Res 20: 236-242. (Pubitemid 351684728)
7. Blatter LA, Wier WG, (1994). Nitric oxide decreases [Ca2+]i in vascular smooth muscle by inhibition of the calcium current. Cell Calcium 15: 122-131.
8. Bohm M, Baumhakel M, Probstfield JL, Schmieder R, Yusuf S, Zhao F, et al,. (2007). Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J 154: 94-101. (Pubitemid 46924800)
9. Bookstein JJ, Vandeberg J, Machado T, (1990). The cavernosal acetylcholine/papaverine response. A practical in vivo method for quantification of endothelium-dependent relaxation. Rationale and experimental validation. Invest Radiol 25: 1168-1174. (Pubitemid 20355778)
10. Buyukafsar K, Un I, (2003). Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. Eur J Pharmacol 472: 235-238. (Pubitemid 37271921)
11. Dorrance AM, Lewis RW, Mills TM, (2002). Captopril treatment reverses erectile dysfunction in male Stroke Prone Spontaneously Hypertensive Rats. Int J Impot Res 14: 494-497. (Pubitemid 36068427)
12. Dusing R, (2003). Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2: 29-34. (Pubitemid 38112142)
13. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, et al,. (2004). Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 291: 2978-2984. (Pubitemid 38802687)
14. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, et al,. (2000). Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 30: 328-338. (Pubitemid 30211093)
15. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L, (2001). Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 14: 27-31. (Pubitemid 32105914)
16. Friedrich EB, Teo KK, Bohm M, (2006). ACE inhibition in secondary prevention: are the results controversial? Clin Res Cardiol 95: 61-67. (Pubitemid 43263068)
17. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW, (1994). Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148. (Pubitemid 24176909)
18. Harrison DG, (1997). Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100: 2153-2157. (Pubitemid 27500136)
19. Hirono Y, Yoshimoto T, Suzuki N, Sugiyama T, Sakurada M, Takai S, et al,. (2007). Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology 148: 1688-1696. (Pubitemid 46457130)
20. Jankowski P, Safar ME, Benetos A, (2009). Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. Curr Pharm Des 15: 571-584.
21. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG, (1997). Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. The J Urology 157: 1920-1925. (Pubitemid 27171811)
22. Kirby M, Jackson G, Betteridge J, Friedli K, (2001). Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 55: 614-618. (Pubitemid 33130348)
23. Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV, (2008). Apolipoprotein E knockout models. Curr Pharm Des 14: 338-351. (Pubitemid 351516858)
24. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, et al,. (2004). Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 6: 937-945. (Pubitemid 39536310)
25. Landmesser U, Harrison DG, (2001). Oxidant stress as a marker for cardiovascular events: ox marks the spot. Circulation 104: 2638-2640. (Pubitemid 33108125)
26. Laufs U, Wassmann S, Czech T, Munzel T, Eisenhauer M, Bohm M, et al,. (2005). Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler Thromb Vasc Biol 25: 809-814. (Pubitemid 40463874)
27. Li H, Forstermann U, (2000). Nitric oxide in the pathogenesis of vascular disease. J Pathol 190: 244-254. (Pubitemid 30141371)
28. Munoz MC, Giani JF, Dominici FP, Turyn D, Toblli JE, (2009). Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens 27: 2409-2420.
29. NIH (1993). NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 270: 83-90.
30. Park JK, Kim SZ, Kim SH, Park YK, Cho KW, (1997). Renin angiotensin system in rabbit corpus cavernosum: functional characterization of angiotensin II receptors. J Urol 158: 653-658. (Pubitemid 27327741)
31. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al,. (1996). Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923.
32. Skultetyova D, Filipova S, Riecansky I, Skultety J, (2007). The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction. Recent Pat Cardiovasc Drug Discov 2: 23-27. (Pubitemid 46813412)
33. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al,. (2009). Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 27: 1360-1369.
34. Speel TG, van Langen H, Meuleman EJ, (2003). The risk of coronary heart disease in men with erectile dysfunction. Eur Urol 44: 366-370; discussion 70-71.
35. Speel TG, Kiemeney LA, Thien T, Smits P, Meuleman EJ, (2005). Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: a pilot study. J Sex Med 2: 207-212. (Pubitemid 40468176)
36. Taniyama Y, Griendling KK, (2003). Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42: 1075-1081. (Pubitemid 37549058)
37. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA, (2005). Erectile dysfunction and subsequent cardiovascular disease. JAMA 294: 2996-3002. (Pubitemid 41817661)
38. Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G, (2004). Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 110: 3062-3067. (Pubitemid 39491999)
39. Weckler N, Leitzbach D, Kalinowski L, Malinski T, Busch AE, Linz W, (2003). Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits. J Renin Angiotensin Aldosterone Syst 4: 191-196. (Pubitemid 37407168)
40. Werner C, Baumhakel M, Teo KK, Schmieder R, Mann J, Unger T, et al,. (2008). RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 97: 418-431.
41. Xie D, Odronic SI, Wu F, Pippen AM, Donatucci CF, Annex BH, (2007). A mouse model of hypercholesterolemia-induced erectile dysfunction. J Sex Med 4: 898-907. (Pubitemid 47079627)
42. Yavuzgil O, Altay B, Zoghi M, Gurgun C, Kayikcioglu M, Kultursay H, (2005). Endothelial function in patients with vasculogenic erectile dysfunction. Int J Cardiol 103: 19-26. (Pubitemid 41074599)
43. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al,. (2008a). Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372: 1174-1183.
44. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al,. (2008b). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559. (Pubitemid 351522739)